1. Zhixiang Chen,^# Harshil Dhruv,^# Xuqing Zhang,^# Rohan Kalyan Rej,^# Longchuan Bai,^# Donna McEachern, Paul Kirchhoff, Rakesh Nagilla, Larry J. Jolivette, Cory T. Rice, Peter Orth, Corey O. Strickland, E. Scott Priestley, Helai P. Mohammad, Meilin Wang, Bo Wen, Duxin Sun, Zhihua Sui, Shaomeng Wang. Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy. Nature Communications, 2025, 16, 4095.

2. Jie Luo,^# Zhixiang Chen,^# Yuanyuan Qiao,^# Jean Ching-Yi Tien, Eleanor Young, Rahul Mannan, Somnath Mahapatra, Rupam Bhattacharyya, Lanbo Xiao, Tongchen He, Sanjana Eyunni, Yuping Zhang, Yang Zheng, Fengyun Su, Xuhong Cao, Rui Wang, Yunhui Cheng, Rithvik Seri, James George, Miriam Shahine, Stephanie J. Miner, Matthew G. Rees, Melissa M. Ronan, Jennifer A. Roth, Ulka Vaishampayan, Mi Wang, Shaomeng Wang, Abhijit Parolia, Arul M. Chinnaiyan. p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer. Nature Genetics, 2025, in press.

3. Zhixiang Chen, Yongwen Jiang, Li Zhang, Yinlong Guo, Dawei Ma. Oxalic diamides and tert-butoxides: Two types of ligands enabling practical access to alkyl aryl ethers via Cu-catalyzed coupling reaction. Journal of the American Chemical Society, 2019, 141, 3541. (ESI高被引论文)

4. Zhixiang Chen,^# Mi Wang,^# Dimin Wu,^# Longchuan Bai, Tianfeng Xu, Hoda Metwally, Yu Wang, Donna McEachern, Lijie Zhao, Ruiting Li, John Takyi-Williams, Meilin Wang, Lu Wang, Qiuxia Li, Bo Wen, Duxin Sun, Shaomeng Wang. Discovery of CBPD-268 as an exceptionally potent and orally efficacious CBP/p300 PROTAC degrader capable of achieving tumor regression. Journal of Medicinal Chemistry, 2024, 67, 5275. (被评为“Featured Article”)

5. Zhixiang Chen,^# Mi Wang,^# Dimin Wu, Lijie Zhao, Hoda Metwally, Wei Jiang, Yu Wang, Longchuan Bai, Donna McEachern, Jie Luo, Meilin Wang, Qiuxia Li, Aleksas Matvekas, Bo Wen, Duxin Sun, Arul M Chinnaiyan, Shaomeng Wang. Discovery of CBPD-409 as a highly potent, selective, and orally efficacious CBP/p300 PROTAC degrader for the treatment of advanced prostate cancer. Journal of Medicinal Chemistry, 2024, 67, 5351.

6. Zhixiang Chen,^# Biao Hu,^# Rohan Kalyan Rej,^# Dimin Wu,^# Ranjan Kumar Acharyya,^# Mingliang Wang,^# Tianfeng Xu,^# Jianfeng Lu, Hoda Metwally, Yu Wang, Donna McEachern, Longchuan Bai, Christina L Gersch, Meilin Wang, Wenjing Zhang, Qiuxia Li, Bo Wen, Duxin Sun, James M Rae, Shaomeng Wang. Discovery of ERD-3111 as a potent and orally Efficacious estrogen receptor PROTAC degrader with strong antitumor activity. Journal of Medicinal Chemistry, 2023, 66, 12559.

7. Zhixiang Chen and Dawei Ma. Cu/N,N^’-dibenzyloxalamide catalyzed N-arylation of heteroanilines. Organic Letters, 2019, 21, 6874.

8. Rohan Kalyan Rej,^# Biao Hu,^# Zhixiang Chen,^# Ranjan Kumar Acharyya,^# Dimin Wu,^# Hoda Metwally, Yu Wang, Wei Jiang, Longchuan Bai, Leticia S Nishimura, Christina L. Gersch, Meilin Wang, Bo Wen, Duxin Sun, Kathryn Carlson, John A. Katzenellenbogen, Guozhang Xu, Weihong Zhang, Wenxue Wu, E. Scott Priestley, Zhihua Sui, James M. Rae, Shaomeng Wang. Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα). Journal of Medicinal Chemistry, 2024, 67, 20933.

9. Ranjan Kumar Acharyya,^# Rohan Kalyan Rej,^# Biao Hu,^# Zhixiang Chen,^# Dimin Wu,^# Jianfeng Lu, Hoda Metwally, Donna McEachern, Yu Wang, Wei Jiang, Longchuan Bai, Jelena Tosovic, Christina L. Gersch, Guozhang Xu, Weihong Zhang, WenXue Wu, E. Scott Priestley, Zhihua Sui, Farzad Sarkari, Bo Wen, Duxin Sun, James M. Rae, Shaomeng Wang. Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer. Journal of Medicinal Chemistry, 2024, 67, 19010.

10. Zhixiang Chen, Mengmeng Ning, Qingan Zou, Hua Cao, Yangliang Ye, Ying Leng, Jianhua Shen. Discovery and structure–activity relationship study of 4-phenoxythiazol-5-carboxamides as highly potent TGR5 agonists. Chemical and Pharmaceutical Bulletin, 2016, 64, 326.

11. Hua Cao, Zhi-Xiang Chen, Kai Wang, Meng-Meng Ning, Qing-An Zou, Ying Feng, Yang-Liang Ye, Ying Leng, Jian-Hua Shen. Intestinally-targeted TGR5 agonists equipped with quaternary ammonium have an improved hypoglycemic effect and reduced gallbladder filling effect. Scientific Reports, 2016, 6, 28676.

^#共同第一作者

国际/美国专利：

1. Zhixiang Chen, Rohan Rej, Xuqing Zhang, Longchuan Bai, Paul Kirchhoff, Shaomeng Wang. IKZF2 degraders and uses thereof, 2023-3-24, WIPO, WO2023183540.

2. Zhixiang Chen, Rohan Rej, Guozhang Xu, Dimin Wu, Ranjan Kumar Acharyya, Mingliang Wang, Biao Hu, Jianfeng Lu, Shaomeng Wang. Indazole derivatives as estrogen receptor degraders, 2023-7-12, WIPO, WO2024015408.

3. Shaomeng Wang, Zhixiang Chen, Dimin Wu, Mi Wang. Small molecule degraders of CBP/p300 proteins, 2022-3-3, WIPO, WO2022187417.

4. Shaomeng Wang, Zhixiang Chen, Rohan Rej, Dimin Wu, Jianfeng Lu, Biao Hu, Mingliang Wang, Ranjan Kumar Acharyya. Small molecule degraders of estrogen receptor with cereblon ligands, 2022-3-4, WIPO, WO2022187588.

5. Guozhang Xu, Zhixiang Chen, Rohan Rej, Ranjan Kumar Acharyya, Dimin Wu, Mingliang Wang, Biao Hu, Jianfeng Lu, Zhenwu Li, E. Scott Priestley, Shaomeng Wang. Tetrahydronaphthalene derivatives as estrogen receptor degraders, 2023-7-12, WIPO, WO2024015412.

6. Shaomeng Wang, Zhixiang Chen, Dimin Wu, Yuk-Ming Siu, Rohan Rej, Ranjan Kumar Acharyya, Weiguo Xiang, Longchuan Bai. Cereblon ligands and uses thereof, 2023-7-12, 美国, US20240059711.

7. Shaomeng Wang, Zhixiang Chen, Dimin Wu, Ranjan Kumar Acharyya, Weiguo Xiang, Rohan Rej, Longchuan Bai, Xuqing Zhang, Guozhang Xu. Cereblon ligands and uses thereof, 2023-7-12, 美国, US20240059704.

8. Rohan Rej, Zhixiang Chen, Mingliang Wang, Dimin Wu, Guozhang Xu, Ranjan Kumar Acharyya, Biao Hu, Jianfeng Lu, Shaomeng Wang. Indole derivatives as estrogen receptor degraders, 2023-7-12, WIPO, WO2024015406.

9. Shaomeng Wang, Rohan Rej, Zhixiang Chen, Longchuan Bai, Ranjan Kumar Acharyya, Dimin Wu, Paul Kirchhoff, Guozhang Xu, Zhenwu Li. Cereblon ligands and uses thereof, 2023-7-11, WIPO, WO2024015340.

10. Shaomeng Wang, Rohan Rej, Zhixiang Chen, Ranjan Kumar Acharyya, Longchuan Bai, Paul Kirchhoff, Guozhang Xu, Xuqing Zhang, Zhenwu Li, Biao Hu, Jianfeng Lu. Cereblon ligands and uses thereof, 2023-03-24, WIPO, WO2023183607.

11. Shaomeng Wang, Zhixiang Chen, Mi Wang, Dimin Wu, Jie Luo, Arul M. Chinnaiyan. Orally active CBP/p300 degraders, 2024-01-22, 美国, US Appl. No. 63/623,680.

12. Shaomeng Wang, Tianfeng Xu, Dimin Wu, Zhixiang Chen, Xin Han, Weiguo Xiang, Rohan Rej, Angelo Aguilar, Longchuan Bai. Cereblon ligands, 2022-03-03, WIPO, WO2022187423.

13. Guozhang Xu, Ranjan Kumar Acharyya, Rohan Rej, Zhixiang Chen, Biao Hu, Jianfeng Lu, Shaomeng Wang. Chroman derivatives as estrogen receptor degraders, 2023-07-12, WIPO, WO2024015409.

14. Arul M. Chinnaiyan, Shaomeng Wang, Abhijit Parolia, Jie Luo, Zhixiang Chen. Use of a CBP/p300 Degrader for the treatment of cancer, 2024-03-11, 美国, US Appl. No. 63/563,534.

15. Shaomeng Wang, Haibin Zhou, Dimin Wu, Longchuan Bai, Ranjan Kumar Acharyya, Donna McEachern, Rohan Rej, Zhixiang Chen, Xuqing Zhang, Guozhang Xu, Zhenwu Li. Compounds and compositions as STAT3 degraders and uses thereof, 2024-02-13, WIPO, WO2024173298.

16. Zhenwu Li, Guozhang Xu, Lalgudi Harikrishnan, Shaomeng Wang, Lingying Leng, Lin Yang, Wenbin Tu, Liyue Huang, Rohan Rej, Weiguo Xiang, Zhixiang Chen, Mi Wang. Compounds and compositions as SMARCA2/4 degraders and uses thereof, 2024-03-13, WIPO, WO2024192064.